content_image/294255.jpg
## Vaprisol ®$_{ }$ 

Cumberland’s newest drug, Vaprisol ® , is a prescription product indicated for the treatment of hospitalized patients with hyponatremia, a common electrolyte disturbance in which the sodium ion concentration in blood plasma is lower than normal. Hyponatremia can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure, cancer and pneumonia. Because the symptoms of hyponatremia can be subtle, it can go unrecognized and untreated – often resulting in longer hospital stays or poor outcomes. 

As one of only two branded products indicated for the treatment of hyponatremia, Vaprisol is the first and only intravenously administered vasopressin receptor antagonist. It works by reducing excess water to increase serum sodium concentration and regulate the water/sodium balance in hospitalized patients. Because it is used exclusively in hospitals, the product complements the activities of the Company’s hospital sales force, which promotes Acetadote and Caldolor. 

Developed and launched commercially by Astellas Pharma US in 2006, Cumberland announced the acquisition of Vaprsiol in March 2014. Following the launch of a promotional campaign to support the product, our sales force began actively marketing it in May with many physicians expressing their interest in seeing support for this product return. 

<img src='content_image/294255.jpg'>

## Hepatoren ®$_{ }$ 

Hepatoren ®  is being developed as an injectable formulation to treat patients suffering from hepatorenal syndrome, a life-threatening condition involving progressive kidney failure for which there is no FDA approved pharmaceutical treatment. Approximately 450,000 patients in the United States suffer from medical conditions that make them susceptible to cirrhosis and a subset of these patients develop hepatorenal syndrome every year. 

Cumberland acquired the rights to ifetroban from Cumberland Emerging Technologies (CET) in early 2011 and began developing it under the brand name Hepatoren. Ifetroban had previously been developed by a large pharmaceutical company through seven Phase II studies targeting significant cardiovascular indications. That development program did not meet all of its goals for these indications, and the product was subsequently donated to Vanderbilt University. Researchers at Vanderbilt identified ifetroban as a safe, active, and potentially valuable compound in treating patients for several new indications. Vanderbilt partnered with CET, Cumberland’s majority-owned subsidiary, to transfer all of the data and manufacturing associated with this product. 

Hepatoren is progressing through clinical development in patients suffering from life- threatening liver and kidney failure. We continue to evaluate the product in a group of leading medical research centers across the U.S. 

“Whether reintroducing a brand to the market or developing a new product candidate, our goal is the same: to provide innovative solutions that address poorly met medical needs. Both of these products not only represent significant opportunity for our Company, but also offer promising treatment for critically ill patients.” 

